Ellen R Bradley1, Marlene Tai2, Michael Hankin3, Joshua D Woolley4. 1. University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America. Electronic address: ellen.bradley@ucsf.edu. 2. University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America; Indiana University School of Medicine, Indianapolis, IN, United States of America. 3. Google, San Francisco, CA, United States of America. 4. University of California, San Francisco, CA, United States of America; San Francisco Veteran's Affairs Medical Center, San Francisco, CA, United States of America.
Abstract
INTRODUCTION: Mentalizing, the ability to infer other people's intentions and emotions, is commonly impaired in schizophrenia and may represent an endophenotype. The hypothalamic neuropeptide oxytocin has been shown to improve mentalizing in men with schizophrenia, but its effects in women remain unclear. Given sex differences in the clinical manifestations of schizophrenia and oxytocin system function, this is an important gap to address. METHODS: We tested the effects of a single-dose oxytocin challenge (40 IU) on mentalizing task performance among 26 women with schizophrenia and 38 healthy control women using a randomized, placebo-controlled, double-blind, crossover design. We aimed to replicate our prior study of oxytocin effects on mentalizing in men with schizophrenia, using the same oxytocin administration procedures and performance-based assessments. We used mixed-effects models and equivalence testing as well as Bayesian hierarchical models to examine oxytocin effects. RESULTS: In contrast to our previous finding in a male sample, oxytocin did not improve mentalizing in this sample of women with schizophrenia. Exploratory analyses showed that higher anti-dopaminergic medication dosage was associated with a decreased response to oxytocin, consistent with previous findings in men. CONCLUSION: These findings provide preliminary evidence that exogenous oxytocin administration may have sex-specific effects on mentalizing in schizophrenia. Inclusion of women in future clinical studies with larger samples is critical, as oxytocin effects observed in men may not extend to women with the disorder. Published by Elsevier Inc.
INTRODUCTION: Mentalizing, the ability to infer other people's intentions and emotions, is commonly impaired in schizophrenia and may represent an endophenotype. The hypothalamic neuropeptide oxytocin has been shown to improve mentalizing in men with schizophrenia, but its effects in women remain unclear. Given sex differences in the clinical manifestations of schizophrenia and oxytocin system function, this is an important gap to address. METHODS: We tested the effects of a single-dose oxytocin challenge (40 IU) on mentalizing task performance among 26 women with schizophrenia and 38 healthy control women using a randomized, placebo-controlled, double-blind, crossover design. We aimed to replicate our prior study of oxytocin effects on mentalizing in men with schizophrenia, using the same oxytocin administration procedures and performance-based assessments. We used mixed-effects models and equivalence testing as well as Bayesian hierarchical models to examine oxytocin effects. RESULTS: In contrast to our previous finding in a male sample, oxytocin did not improve mentalizing in this sample of women with schizophrenia. Exploratory analyses showed that higher anti-dopaminergic medication dosage was associated with a decreased response to oxytocin, consistent with previous findings in men. CONCLUSION: These findings provide preliminary evidence that exogenous oxytocin administration may have sex-specific effects on mentalizing in schizophrenia. Inclusion of women in future clinical studies with larger samples is critical, as oxytocin effects observed in men may not extend to women with the disorder. Published by Elsevier Inc.
Entities:
Keywords:
Oxytocin; Schizophrenia; Sex differences; Social cognition
Authors: Leah H Rubin; Siyi Li; Li Yao; Sarah K Keedy; James L Reilly; Scot K Hill; Jeffrey R Bishop; C Sue Carter; Hossein Pournajafi-Nazarloo; Lauren L Drogos; Elliot Gershon; Godfrey D Pearlson; Carol A Tamminga; Brett A Clementz; Matcheri S Keshavan; Su Lui; John A Sweeney Journal: Schizophr Res Date: 2018-07-06 Impact factor: 4.939
Authors: Julia Longenecker; Jamie Genderson; Dwight Dickinson; James Malley; Brita Elvevåg; Daniel R Weinberger; James Gold Journal: Schizophr Res Date: 2010-06 Impact factor: 4.939
Authors: Ellen R Bradley; Alison Seitz; Andrea N Niles; Katherine P Rankin; Daniel H Mathalon; Aoife O'Donovan; Joshua D Woolley Journal: Schizophr Res Date: 2019-08-12 Impact factor: 4.939
Authors: Jana Lieberz; Dirk Scheele; Franny B Spengler; Tatjana Matheisen; Lìa Schneider; Birgit Stoffel-Wagner; Thomas M Kinfe; René Hurlemann Journal: Neuropsychopharmacology Date: 2019-11-30 Impact factor: 8.294